GSK buys Nuvalent for $10.6bn to shield oncology pipeline from HIV patent cliff
The acquisition secures two late-stage lung cancer medicines and aims to offset revenue declines expected between 2028 and 2031, prompting mixed but generally cautious reactions from major banks.
GlaxoSmithKline has completed the acquisition of US biotech firm Nuvalent for $10.6 billion (£8 billion), a move designed to bolster its oncology portfolio and mitigate anticipated revenue losses from HIV patent expiries between 2028 and 2031. The transaction secures rights to two late-stage lung cancer medicines, neladalkib and zidesamtinib, which target genetically defined forms of non-small cell lung cancer and are expected to face regulatory decisions within months.
The deal represents a continuation of the oncology rebuild initiated by former chief executive Emma Walmsley, aimed at reducing investor concerns over the eventual loss of exclusivity on GSK’s HIV portfolio. UBS described the acquisition as a "strong strategic fit", projecting combined peak sales of $3.75 billion for the assets. The bank argued the drugs could help smooth the earnings drag associated with the impending HIV patent cliffs, viewing the purchase as a logical step in the company’s strategic evolution.
Shore Capital was more enthusiastic about the transaction, raising its target price for GSK shares to 2,600p from 2,500p and reiterating a 'buy' recommendation. Analyst Sean Conroy noted that the deal lays the foundations for a dedicated lung cancer franchise and weakens the bear case centred on the HIV patent cliff. He stated that the shares, on his revised numbers, imply a 13 times 2027 price-to-earnings ratio, which he described as undemanding compared to peers, keeping GSK as his preferred UK pharma name over competitors such as AstraZeneca.
Deutsche Bank maintained a more measured stance, keeping a 'hold' rating and a 1,900p target. Analyst Emmanuel Papadakis noted that GSK is paying roughly three times consensus peak sales forecasts for assets targeting well-understood markets. While characterising the premium as modest and reasonable for accelerating the oncology rebuild, Papadakis highlighted that the key ALKAZAR trial will not read out for several years, meaning the deal’s full efficacy remains unproven.
UBS also maintained its 'neutral' rating and 1,940p target, reflecting a consensus that while the strategic logic is sound, the debate now centres on how much upside remains after shelling out a significant amount for relatively mature assets. Deutsche Bank noted that the assets bring "relatively derisked and imminent oncology revenue streams" but exist in "familiar if somewhat derivative and crowded spaces", suggesting the company is bringing forward revenue streams rather than creating entirely new value.
